Strides Pharma Science Limited — Important, 11-07-2025: General Updates

Strides Pharma Science Limited reported 95.22% of standalone turnover from exports, with no marketing in India. The company operates 5 manufacturing plants in India and 3 international facilities, serving 106 countries. FY25 saw increased board diversity (25% women) and 62% independent directors. No Class I product recalls occurred. Strides paid a ₹1.51 Cr compounding fee for an R&D spend shortfall related to ESOP approvals. Sustainability efforts include 100% sustainable sourcing of APIs and packaging, 51.6% renewable energy use, and carbon reduction initiatives. Employee well-being spend rose to 2.48% of revenue. No major safety incidents reported; grievance mechanisms and human rights policies are robust. CSR initiatives benefited over 11,000 people, focusing on healthcare, education, and vocational training.